Analysis Of Income And Expense [Abstract]
| Concept |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Analysis of income and expense [abstract] | |||||||||||||||||
| Revenue [abstract] | |||||||||||||||||
| Revenue |
469,637
EUR
|
— | — | — | — | — | — | — | — | — | — |
487,342
EUR
|
— | — | — | — | — |
| Material income and expense [abstract] | |||||||||||||||||
| Impairment loss (reversal of impairment loss) on trade receivables [abstract] | |||||||||||||||||
| Impairment loss recognised in profit or loss, trade receivables |
562,000
EUR
|
— | — | — | — | — | — | — | — | — | — |
317,000
EUR
|
— | — | — | — | — |
| Reversal of impairment loss recognised in profit or loss, trade receivables |
215,000
EUR
|
— | — | — | — | — | — | — | — | — | — |
83,000
EUR
|
— | — | — | — | — |
| Expenses by nature [abstract] | |||||||||||||||||
| Raw materials and consumables used |
30,599
EUR
|
— | — | — | — | — | — | — | — | — | — |
9,949
EUR
|
— | — | — | — | — |
| Classes of employee benefits expense [abstract] | |||||||||||||||||
| Expense from share-based payment transactions with employees |
513,000
EUR
|
— | — | — | — | — | — | — | — | — | — |
2,331
EUR
|
— | — | — | — | — |
| Employee benefits expense |
35,292
EUR
|
— | — | — | — | — | — | — | — | — | — |
27,030
EUR
|
— | — | — | — | — |
| Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract] | |||||||||||||||||
| Depreciation and amortisation expense [abstract] | |||||||||||||||||
| Depreciation and amortisation expense |
164,114
EUR
|
— | — | — | — | — | — | — | — | — | — |
152,619
EUR
|
— | — | — | — | — |
| Other expenses, by nature |
116,487
EUR
|
— | — | — | — | — | — | — | — | — | — |
117,134
EUR
|
— | — | — | — | — |
| Disclosure of attribution of expenses by nature to their function [text block] | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of attribution of expenses by nature to their function [abstract] | |||||||||||||||||
| Disclosure of attribution of expenses by nature to their function [line items] | |||||||||||||||||
| Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract] | |||||||||||||||||
| Share of profit (loss) of associates and joint ventures accounted for using equity method |
927,000
EUR
|
— | — | — | — | — | — | — | — | — | — |
561,000
EUR
|
— | — | — | — | — |
| Income tax relating to components of other comprehensive income [abstract] | |||||||||||||||||
| Income tax relating to components of other comprehensive income that will be reclassified to profit or loss |
8,545
EUR
|
— | — | — | — | — | — | — | — | — | — |
1,724
EUR
|
— | — | — | — | — |
| Comprehensive income, continuing and discontinued operations [abstract] | |||||||||||||||||
| Comprehensive income |
232,068
EUR
|
4,668
EUR
|
696,000
EUR
|
174,074
EUR
|
53,329
EUR
|
226,704
EUR
|
14,000
EUR
|
713,000
EUR
|
54,000
EUR
|
153,353
EUR
|
74,709
EUR
|
69,627
EUR
|
78,490
EUR
|
394,000
EUR
|
4,688
EUR
|
245,000
EUR
|
37,000
EUR
|
| Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract] | |||||||||||||||||
| Comprehensive income, attributable to owners of parent |
226,704
EUR
|
— | — | — | — | — | — | — | — | — | — |
74,709
EUR
|
— | — | — | — | — |
| Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract] | |||||||||||||||||
| Comprehensive income, attributable to non-controlling interests |
696,000
EUR
|
— | — | — | — | — | — | — | — | — | — |
394,000
EUR
|
— | — | — | — | — |